Wilson Sonsini Goodrich & Rosati and Pinsent Masons advised 4D pharma plc on the deal. 4D pharma plc, a Leeds, UK-based pharmaceutical company leading the development...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Everlywell on the deal, while Choate represented PWNHealth. Everlywell, a leading digital health company, announced that it has acquired PWNHealth...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Savara Inc. on the deal. Savara Inc., an orphan lung disease company, announced the closing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Viz.ai on the deal. Viz.ai, the leader in AI-driven modern care coordination, announced that it has raised $71 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk advised the representatives of the underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ventyx Biosciences on the deal. Taylor Wessing advised Oppilan Pharma Limited and Zomagen Biosciences Limited. Ventyx Biosciences, a clinical-stage biotechnology...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Maples and Calder advised First High-School Education Group Co. on the deal. Kirkland & Ellis International LLP acted as US...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Legance, PwC TLS, White & Case, Wilson Sonsini Goodrich & Rosati, advised on the matter. Legance advised Sumo Logic Inc. with a team including...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised project 44, Inc. on the deal. Project 44, Inc., the global leader in supply chain visibility, announced it has acquired...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised NightDragon Acquisition Corp. on the deal, while Davis Polk advised the representative of the several underwriters. NightDragon Acquisition Corp. closed...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Cullgen Inc. on the deal. Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™...
You must be a Standard 1 Year member to access this content.
